Scott E Wolkenberg

US Patent:

7576083, Aug 18, 2009

Filed:

Apr 29, 2005

Appl. No.:

11/579234

Inventors:

Craig W. Lindsley - Schwenksville PA, US
Scott E. Wolkenberg - Lawrenceville NJ, US
Zhijian Zhao - Wilmington DE, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 31/5377
C07D 413/06
C07D 413/14

US Classification:

5142355, 544106, 544111, 544124, 544129, 5142312, 5142315

Abstract:

The present invention is directed to morpholinyl piperidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.

US Patent:

7776886, Aug 17, 2010

Filed:

Sep 26, 2005

Appl. No.:

11/664190

Inventors:

Craig W. Lindsley - Schwenksville PA, US
David D. Wisnoski - Quakertown PA, US
Scott E. Wolkenberg - Jenkintown PA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/445
C07D 211/96

US Classification:

514331, 514233, 546184

Abstract:

The present invention is directed to cyclopropyl piperidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neuro-transmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.

US Patent:

7825135, Nov 2, 2010

Filed:

Mar 23, 2005

Appl. No.:

10/593950

Inventors:

Wesley Blackaby - Harlow, GB
Mark E. Duggan - Wellesley MA, US
David Hallett - Harlow, GB
George D. Hartman - Landsdale PA, US
Andrew S. Jennings - Harlow, GB
William H. Leister - Quakertown PA, US
Richard T. Lewis - Harlow, GB
Craig W. Lindsley - Schwenksville PA, US
Elizabeth Naylor - Harlow, GB
Leslie J. Street - Harlow, GB
Yi Wang - North Wales PA, US
David D. Wisnoski - Quakertown PA, US
Scott E. Wolkenberg - Jenkintown PA, US
Zhijian Zhao - Wilimington DE, US

Assignee:

Merck Sharp & Dohme Limited - Hertfordshire
Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/435
A61K 31/445

US Classification:

514318, 514277

Abstract:

The present invention is directed to pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl piperidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.

US Patent:

7947714, May 24, 2011

Filed:

Oct 27, 2006

Appl. No.:

12/084027

Inventors:

David Hallett - Buckinghamshire, GB
Craig W. Lindsley - Brentwood TN, US
Elizabeth M. Naylor - Needham MA, US
Zhijian Zhao - Wilmington DE, US
Cory R. Theberge - Elkins Park PA, US
Scott E. Wolkenberg - Jenkintown PA, US
M. Brad Nolt - Gilbertsville PA, US

Assignee:

Merck, Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/445
C07D 211/32

US Classification:

514331, 546233, 546234

Abstract:

The present invention is directed to piperidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.

US Patent:

7973059, Jul 5, 2011

Filed:

Oct 17, 2006

Appl. No.:

11/992919

Inventors:

Scott Wolkenberg - Jenkintown PA, US
Mark T. Bilodeau - Lansdale PA, US
M. Brad Nolt - Blue Bell PA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/44
C07D 213/30

US Classification:

514332, 514335, 546255, 546261, 546262, 546264, 546265, 546266

Abstract:

The present invention relates to compounds having the structure useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.

US Patent:

8148535, Apr 3, 2012

Filed:

Oct 17, 2006

Appl. No.:

12/083475

Inventors:

B. Wesley Trotter - Glenside PA, US
Kausik K. Nanda - Norristown PA, US
Scott Wolkenberg - Jenkintown PA, US
M. Brad Nolt - Blue Bell PA, US
Peter Manley - Harleysville PA, US
Nathan R. Kett - Perkiomenville PA, US
Mark T. Bilodeau - Lansdale PA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 401/14
A61K 31/4402
A61K 31/4406
A61K 31/4409

US Classification:

546256, 514332

Abstract:

The present invention relates to compounds having the structure useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.

US Patent:

8278317, Oct 2, 2012

Filed:

Jul 18, 2006

Appl. No.:

11/988393

Inventors:

B. Wesley Trotter - Glenside PA, US
Kausik K. Nanda - Norristown PA, US
Scott E. Wolkenberg - Jenkintown PA, US
M. Brad Nolt - Bluebell PA, US
David Wisnoski - Quakertown PA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/4406
A61K 31/4439
C07D 401/02
C07D 413/02
C07D 213/46

US Classification:

514277, 514340, 5462684, 5462691, 5462714, 546342

Abstract:

The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.

US Patent:

8530483, Sep 10, 2013

Filed:

May 28, 2009

Appl. No.:

12/995314

Inventors:

James C. Barrow - Arnold MD, US
Scott Harrison - Etkins Park PA, US
James Mulhearn - Saint Davids PA, US
Cyrille Sur - Harleysville PA, US
David L. Williams - Telford PA, US
Scott Wolkenberg - Jenkintown PA, US
Eric Hostetler - Collegeville PA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A01N 43/90
A01N 43/42
A61K 31/519
A61K 31/44
C07D 239/00
C07D 471/00
C07D 491/00
C07D 513/02
C07D 515/02
C07D 471/02
C07D 491/02
C07D 498/02

US Classification:

5142601, 514301, 514302, 544255, 546114, 546115

Abstract:

The present invention relates to novel amyloid binding compounds of formula (I) and methods for measuring effects of the compounds, by measuring changes of amyloid plaque level in living patients. More specifically, the present invention relates to a method of using the compounds of this invention as tracers in positron emission tomography (PET/) imaging to study amyloid deposits in brain in vivo to allow diagnosis of Alzheimer's disease. Thus, the present invention relates to use of the novel amyloid binding compounds as a diagnostic. The invention further relates to a method of measuring clinical efficacy of Alzheimer's disease therapeutic agents. Specifically, the present invention relates to novel aryl or heteroaryl substituted azabenzoxazole derivatives, compositions, and therapeutic uses and processes for making such compounds, or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof, wherein: X is O or S; A and Y independently are N, or CH.